Literature DB >> 29444719

The significance of atherosclerosis in hypertensive patients with epistaxis.

S Elwany1, A A Ibrahim1, A I Soliman1, R Bazak1, H A Ibrahim2.   

Abstract

BACKGROUND: The relationship between hypertension and epistaxis is controversial and poorly understood. The present research investigated atherosclerosis as a potential risk factor in hypertensive patients with epistaxis.
METHODS: A prospective study of 141 hypertensive patients with epistaxis was conducted. The laboratory tests included full blood count, lipid profile and coagulation profile. All patients underwent funduscopic examination of the eye and were classified in terms of four retinopathy grades.
RESULTS: There were strong positive correlations between the number of nosebleeds and retinopathy grade and low-density lipoprotein cholesterol level. There were weak correlations between the number of nosebleeds and blood pressure readings and triglycerides levels. Patients with grade III retinopathy, suggesting atherosclerosis, suffered from more frequent nosebleeds than other patients.
CONCLUSION: Atherosclerosis is one of the potential risk factors in hypertensive patients with epistaxis. This may have an impact on treatment choices.

Entities:  

Keywords:  Atherosclerosis; Cholesterol; Epistaxis; Hypertension; Retina

Mesh:

Substances:

Year:  2018        PMID: 29444719     DOI: 10.1017/S0022215118000221

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  2 in total

1.  Association of Hypertension With the Risk and Severity of Epistaxis.

Authors:  Hayoung Byun; Jae Ho Chung; Seung Hwan Lee; Jiin Ryu; Changsun Kim; Jeong-Hun Shin
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-09-10       Impact factor: 6.223

2.  Analysis of Bleeding Site to Identify Associated Risk Factors of Intractable Epistaxis.

Authors:  Zhenpeng Liao; Jianling Guo; Jiaoping Mi; Wei Liao; Shulin Chen; Yili Huang; Yingxiang Xu; Jun Zhang; Qintai Yang; Haiyu Hong
Journal:  Ther Clin Risk Manag       Date:  2021-08-12       Impact factor: 2.423

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.